Stability, Prognostic Factors and Survival of Spinal Bone Metastases in Malignant Melanoma Patients after Palliative Radiotherapy

2016 ◽  
Vol 102 (2) ◽  
pp. 156-161 ◽  
Author(s):  
Tilman Bostel ◽  
Robert Förster ◽  
Ingmar Schlampp ◽  
Robert Wolf ◽  
Andre Franke Serras ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Malignant Melanoma ◽  
Bone Metastases ◽  
Palliative Radiotherapy ◽  
Spinal Bone Metastases ◽  
Melanoma Patients

scholarly journals Stability and survival analysis of elderly patients with osteolytic spinal bone metastases after palliative radiotherapy

2019 ◽  
Vol 195 (12) ◽  
pp. 1074-1085 ◽  
Author(s):  
Tilman Bostel ◽  
Robert Förster ◽  
Ingmar Schlampp ◽  
Tanja Sprave ◽  
Sati Akbaba ◽  
...  
Keyword(s):  
Survival Analysis ◽  
Elderly Patients ◽  
Bone Metastases ◽  
Palliative Radiotherapy ◽  
Spinal Bone Metastases

scholarly journals Survival and stability of patients with urothelial cancer and spinal bone metastases after palliative radiotherapy

2017 ◽  
Vol 52 (2) ◽  
pp. 189-194
Author(s):  
Robert Foerster ◽  
Katharina Hees ◽  
Thomas Bruckner ◽  
Tilman Bostel ◽  
Ingmar Schlampp ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Urothelial Cancer ◽  
Cell Cancer ◽  
Palliative Radiotherapy ◽  
Local Response ◽  
Mineral Density ◽  
Hounsfield Units ◽  
Spinal Bone Metastases ◽  
Fractionation Schedules

Abstract Background The aim of the study was to analyze survival and stability of patients with urothelial cell cancer and spinal bone metastases (SBM) after radiotherapy (RT). Furthermore, to assess the effects of RT on bone mineral density (BMD) as a local response in SBM after RT. Patients and methods Survival of 38 patients with 132 SBM from urothelial cancer, treated from January 2000 to January 2012, was calculated. Stability of irradiated thoracic and lumbar SBM was retrospectively evaluated in computed tomography (CT) scans using the validated Taneichi et al. score. Difference in BMD, measured in Hounsfield units (HU), of the SBM before and at 3 and 6 months after RT was analyzed. Results All patients died during follow-up. Overall survival (OS) after 6 months, 1 year and 2 years was 90%, 80% and 40%, respectively. Bone survival (BS) was 85%, 64% and 23% after 6 months, 1 year and 2 years, respectively. Survival from start of RT (RTS) was 42% after 6 months, 18% after 1 year and 5% after 2 years. Only 11% received bisphosphonates. Stability did not improve at 3 or 6 months after RT. BMD increased by 25.0 HU ± 49.7 SD after 3 months (p = 0.001) and by 24.2 HU ± 52.2 SD after 6 months (p = 0.037). Pain relief (> 2 points on the visual analogue scale) was achieved in only 27% of patients. Conclusions Benefit from palliative RT of painful or unstable SBM is limited in these patients and they should be carefully selected for RT. Shorter fractionation schedules may be preferred and outcome may improve with concomitant bisphosphonates.

Prognostic Factors in Advanced Metastatic and Recurrent Melanoma Treated with DTIC

1987 ◽  
Vol 73 (1) ◽  
pp. 49-50 ◽  
Author(s):  
Marek Pawlicki ◽  
Jan Skolyszewski ◽  
Barbara Stryjewska ◽  
Henryk Nosek
Keyword(s):  
Prognostic Factors ◽  
Malignant Melanoma ◽  
Soft Tissue ◽  
Bone Metastases ◽  
Locoregional Recurrence ◽  
Lung Metastases ◽  
Metastatic Malignant Melanoma

Thirty-five patients with recurrent and 25 patients with metastatic malignant melanoma after previous radical locoregional surgery were treated with DTIC at the Institute of Oncology in Krakow between 1976 and 1981. Complete and partial remissions were observed in 19/60, i.e., in 31 % of the patients. Our results show an advantage for patients with locoregional recurrence, soft-tissue and lung metastases, provided that the largest deposit is no larger than 5 cm in diameter. There is little chance of remission in patients with liver and bone metastases.

scholarly journals Resistance training concomitant to radiotherapy of spinal bone metastases – survival and prognostic factors of a randomized trial

2016 ◽  
Vol 11 (1) ◽  
Author(s):  
Harald Rief ◽  
Thomas Bruckner ◽  
Ingmar Schlampp ◽  
Tilman Bostel ◽  
Thomas Welzel ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Resistance Training ◽  
Bone Metastases ◽  
Randomized Trial ◽  
Spinal Bone Metastases

scholarly journals Survival and stability of patients with urothelial cancer and spinal bone metastases after palliative radiotherapy

2017 ◽  
Vol 52 (2) ◽  
pp. 189-194 ◽  
Author(s):  
Robert Foerster ◽  
Katharina Hees ◽  
Thomas Bruckner ◽  
Tilman Bostel ◽  
Ingmar Schlampp ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Urothelial Cancer ◽  
Cell Cancer ◽  
Palliative Radiotherapy ◽  
Local Response ◽  
Mineral Density ◽  
Hounsfield Units ◽  
Spinal Bone Metastases ◽  
Fractionation Schedules

Abstract Background The aim of the study was to analyze survival and stability of patients with urothelial cell cancer and spinal bone metastases (SBM) after radiotherapy (RT). Furthermore, to assess the effects of RT on bone mineral density (BMD) as a local response in SBM after RT. Patients and methods Survival of 38 patients with 132 SBM from urothelial cancer, treated from January 2000 to January 2012, was calculated. Stability of irradiated thoracic and lumbar SBM was retrospectively evaluated in computed tomography (CT) scans using the validated Taneichi et al. score. Difference in BMD, measured in Hounsfield units (HU), of the SBM before and at 3 and 6 months after RT was analyzed. Results All patients died during follow-up. Overall survival (OS) after 6 months, 1 year and 2 years was 90%, 80% and 40%, respectively. Bone survival (BS) was 85%, 64% and 23% after 6 months, 1 year and 2 years, respectively. Survival from start of RT (RTS) was 42% after 6 months, 18% after 1 year and 5% after 2 years. Only 11% received bisphosphonates. Stability did not improve at 3 or 6 months after RT. BMD increased by 25.0 HU ± 49.7 SD after 3 months (p = 0.001) and by 24.2 HU ± 52.2 SD after 6 months (p = 0.037). Pain relief (> 2 points on the visual analogue scale) was achieved in only 27% of patients. Conclusions Benefit from palliative RT of painful or unstable SBM is limited in these patients and they should be carefully selected for RT. Shorter fractionation schedules may be preferred and outcome may improve with concomitant bisphosphonates.

scholarly journals EP-1652 Stability and survival of elderly patients after palliative radiotherapy of spinal bone metastases

2019 ◽  
Vol 133 ◽  
pp. S889-S890
Author(s):  
T. Bostel ◽  
R. Förster ◽  
I. Schlampp ◽  
T. Sprave ◽  
S. Akbaba ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Bone Metastases ◽  
Palliative Radiotherapy ◽  
Spinal Bone Metastases

scholarly journals Prognostic factors associated with survival in patients with symptomatic spinal bone metastases: a retrospective cohort study of 1 043 patients

2014 ◽  
Vol 16 (7) ◽  
pp. 991-998 ◽  
Author(s):  
L. Bollen ◽  
Y. M. van der Linden ◽  
W. Pondaag ◽  
M. Fiocco ◽  
B. P. M. Pattynama ◽  
...  
Keyword(s):  
Cohort Study ◽  
Prognostic Factors ◽  
Bone Metastases ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Factors Associated ◽  
Spinal Bone Metastases
Sign in / Sign up

Export Citation Format

Share Document